Arphra
live
S&P 5000.34
NASDAQ0.00
DOW50,872.11+2.56%
VIX20.95+16.00%
US10Y4.53+1.21%
EUR/USD1.1576+0.37%
GOLD4,242.2+4.38%
WTI85.83-7.70%
BTC63,338+3.09%
S&P 5000.34
NASDAQ0.00
DOW50,872.11+2.56%
VIX20.95+16.00%
US10Y4.53+1.21%
EUR/USD1.1576+0.37%
GOLD4,242.2+4.38%
WTI85.83-7.70%
BTC63,338+3.09%

LLY

Eli Lilly and Company
HealthcareDrug Manufacturers - GeneralUSUSDPeers →
$1,142.18
LiveJun 12, 2026
AI Brief
Market cap
$1.08T
52w range
623.78 – 1182.73
P / E
EPS · FY 2025
$22.95
Volume
1.17M
Revenue · FY 2025
$65.18B
+44.70% YoY

Explain this page

Arphra AI
Business description
· company · SEC profile

Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Founded
IPO
Jun 01, 1972
Employees
47,000
HQ
Indianapolis, IN
CEO
David A. Ricks
CFO
Lucas E. Montarce
Exchange
NYSE
Fiscal year
Identifiers
· company_identifiers
CIK0000059478
CUSIP532457108
ISINUS5324571083
FIGILLY US
LEI
Cross-listings
· companies · ISIN
  • LLYPrimaryNew York Stock ExchangeusUSD$1.09T
  • LLY.DEDeutsche Börse XETRAusEUR$1.1T
  • LLY.TOToronto Stock ExchangeusCAD$1.02T
  • LLY.SWSIX Swiss ExchangeusCHF$901.23B
The global universe keeps only the primary listing; the other venues for this security are shown here.